• 生物活性

靶点及简介 ：Omalizumab 奥马珠单抗是一种结合免疫球蛋白E(IgE)的人源化IgG1κ单抗，其可阻断IgE介导的过敏级联反应，减少炎症因子释放。

Omalizumab (anti-IgE)是一种针对人免疫球蛋白 E (IgE)的重组人源化单克隆抗体，KD 为 0.393 nM。Omalizumab (anti-IgE)与人 FcγRIIb 受体结合的 KD 为 6.37 uM。

Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Omalizumab inhibits the binding of IgE to FcεRI on mast cells and basophils by binding to an antigenic epitope on IgE that overlaps with the site to which FcεRI binds. When IgE is bound to the receptor, the antigenic epitope on IgE to which omalizumab binds is sterically hindered by the receptor and is not accessible to omalizumab binding, thus averting the anaphylactic effects presumably unavoidable with an ordinary anti-IgE antibody . Furthermore, although the peptide elements on IgE involved in binding to low affinity IgE receptor (FcεRII) on many cell types are different from the peptide elements involved in binding to FcεRI, omalizumab, by steric hindrance, also prevents binding of IgE to FcεRII.

体内研究

Omalizumab (anti-IgE) is effective in controlling the allergic symptoms of allergic rhinitis by lowering inflammatory mediator CysLT levels of nasal lavage in an experimental allergic rhinitis mode.

• 验证及参考文献

验证：

参考文献：

[1] Chang TW, et al. Adv Immunol. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.

[2] Schulman ES. Am J Respir Crit Care Med. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.

• 溶解度及制备方案
  

  Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
  1 mM	0.0069 mL	0.0345 mL	0.0689 mL
  5 mM	0.0014 mL	0.0069 mL	0.0138 mL
  10 mM	0.0007 mL	0.0034 mL	0.0069 mL